Home | About PM | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Pharmacognosy Magazine
Search Article 
Advanced search 
Year : 2022  |  Volume : 18  |  Issue : 79  |  Page : 746-751

Pinocembrin shows antithrombotic activity on the thrombosis-induced experimental rats

1 Department of General Surgery, General Hospital of Northern Theater Command, Shenyang, 110016, China
2 Department of Interventional Therapy, General Hospital of Northern Theater Command, Shenyang, 110016, China

Correspondence Address:
Liwei Zhang
Department of Interventional Therapy, General Hospital of Northern Theater Command, Shenyang, 110016
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/pm.pm_535_21

Rights and Permissions

Background: Thrombosis is a major complication and is responsible for cardiovascular diseases (CVDs). The majority of CVDs like stroke, coronary syndrome, and vascular ailments are tightly connected to venous/arterial blood clots. The present research work was planned to address the curative benefits of pinocembrin against thrombosis in the experimental animal model. Materials and methods: The male Wistar rats were employed in this research work and the thrombosis was provoked to the rats via electrical shock by standard method. Animals were treated with 25 and 50 mg/kg of pinocembrin orally. The 20 mg/kg of aspirin was used as a positive control. The level of thrombin-provoked platelet aggregation was performed using the standard method. The plasma coagulation parameters were examined using an automated blood coagulation analyzer. The status of tissue factor pathway inhibitor (TFPI), thromboxane-B2 (TX-B2), 6-keto-PGF1α, and TXB2/6-keto-PGF1α (T/K) was investigated using assay kits. The levels of urokinase-type plasminogen activator (u-PA), tissue-type plasminogen activator (t-PA), PAI-1, and t-PA/PAI-1 were quantified using assay kits. Results: The pinocembrin treatment appreciably prolonged the coagulation parameter time periods like activated partial thromboplastin time, thrombin time, and TP. Pinocembrin also elevated the TFPI, 6-Keto-PGF1α, u-PA, and t-PA status and reduced the platelet aggregation, TX-B2, T/K, PAI-1, and t-PA/PAI-1 levels in the experimental rats. Conclusion: The findings of this work suggested that the pinocembrin exhibited potent antithrombotic activity and it could be a potential candidate to treat the thrombosis in the future.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded13    
    Comments [Add]    

Recommend this journal